Third in the ZBIO series. Prior: "The Crash They Bought" (Apr 3) and "Six Weeks Later" (May 17).
On June 2, the New England Journal of Medicine published the full Phase 3 INDIGO trial results for obexelimab in IgG4-related disease. Simultaneously presented at the EULAR Congress in London.
The NEJM is not a conference abstract. It is not a press release. It is the single most prestigious venue in clinical medicine, with a rejection rate above 95%. Simultaneous publication means the editors considered this data significant enough to coordinate with the congress. That almost never happens for a pre-revenue biotech's first pivotal trial.
ZBIO closed at $16.91. Down 7.8%.
What the Journal Said
The data got better, not just confirmed.
PRIMARY ENDPOINT
56%
flare risk reduction
HR 0.44, p=0.0005
FLARE-FREE AT WEEK 52
73.2%
vs 45.4% placebo
COMPLETE REMISSION
37.1%
vs 19.6% placebo
p=0.0049
STEROID RESCUE USE
–65%
329 mg vs 930 mg
p=0.0042
Complete remission and glucocorticoid toxicity data were new. The topline in January showed efficacy. The NEJM paper shows something rarer: a drug that works and reduces the harms of the standard treatment it replaces. Grade 3+ adverse events were lower on drug than placebo — 11.3% vs 23.7%. No deaths on obexelimab. One on placebo.
If you designed the perfect Phase 3 result for a first-in-class drug in an orphan indication with no approved therapy, it would look like this dataset.
Fifteen Days
CEO Leon Moulder bought $1.01 million of ZBIO on May 18. The BLA was filed ten days later. The NEJM published fifteen days after that.
He knew. Not in the insider-trading sense — BLA submissions and NEJM acceptances don't happen overnight. They take months of preparation. He knew the trajectory of events that was about to unfold, and he put another million dollars of his own money into the stock before any of it became public.
This is his sixth purchase since January. Total insider buying: $18.5 million. Sells: zero.
The Divergence
SCIENCE
NEJM published
BLA filed. All endpoints met.
INSIDERS
$18.5M bought
Six rounds. Zero sells.
MARKET
$16.91 ↓7.8%
9.36M shares short. 22.5% SI.
Analyst consensus target: $43.14. Guggenheim: $55. The median analyst sees 155% upside from here. Shorts see something else — or they see the same thing and are betting on timing, not science.
Every catalyst that was "upcoming" in my first two posts has now arrived. The BLA is filed. The data is peer-reviewed. The safety profile is clean. And the stock is lower than when any of these events were still uncertain.
Uncertainty was priced in at $19. Certainty is priced at $16.91.
I don't know when this resolves. FDA review will take 10–12 months from the BLA filing. The SunStone lupus readout is Q4. Short interest at 7.48 days to cover means unwinding takes weeks, not hours.
But the pattern is now complete: insiders bought $18.5 million of a stock whose pivotal data just passed the highest bar in medicine. The New England Journal of Medicine doesn't publish noise. Neither do CEOs who buy six times in five months.